Hair loss

Woman experiencing hair loss
#Alopecia #Hair loss #Pelage Pharmaceuticals #Phase II trial

‘Molecular switch’ could reverse the effects of alopecia

A Phase IIa clinical trial has begun evaluating the safety and efficacy of Pelage Pharmaceuticals’ PP405, a novel topical small molecule, for the treatment of androgenetic alopecia (pattern baldness). The company is enrolling 60 women and men for the clinical study. PP405 is designed to reactivate… Read More

#Editor's Choice #News

Alopecia
#Alopecia #Dermatology #Hair loss #JAK inhibitor #MHRA

First oral therapy for severe alopecia areata approved in UK

The MHRA has granted marketing authorisation for Eli Lilly’s baricitinib (Olumiant), the first licensed JAK inhibitor for the treatment of severe alopecia areata in adult patients.   The authorisation was based on BRAVE-AA1 and BRAVE-AA2 studies which both met the primary endpoint of the proportion of patients achieving SALT ≤20 (i.e.,… Read More

#News #Regulatory